cerebral amyloid angiopathy: Hereditary cerebral hemorrhage with amyloidosis (HCHWA) describes a group of rare familial central nervous system disorders characterized by amyloid deposition in the cerebral blood vessels leading to hemorrhagic and non-hemorrhagic strokes, focal neurological deficits, and progressive cognitive decline eventually leading to dementia.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
205 |
4. Check minimum number of eventsNone |
205 |
5. Include endpointsNone |
205 |
6. Filter based on genotype QC (FinnGen only) |
182 |
Control definitions (FinnGen only)
- Control exclude
- I9_CEREBVASC
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Cerebral amyloid angiopathy
based on the number of shared cases.
Similar with more cases:
- Cerebrovascular diseases
- Neurological diseases, wide definition
- Cardiovascular diseases
- Any operation in hilmo
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 791 | 364 | 421 |
| Only index persons | 742 | 344 | 398 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 74.51 | 75.07 | 73.97 |
| Only index persons | 74.47 | 75.07 | 73.94 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 182 | 75 | 107 |
| Unadjusted period prevalence (%) | 0.04 | 0.03 | 0.05 |
| Median age at first event (years) | 74.69 | 74.29 | 74.97 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 190
- Matched controls
- 1900
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
I68.0*E85.9
ICD-10 Finland
Cerebral amyloid angiopathy
+∞
208.9
160
*
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
15.1
66.5
71
72
I68.0
ICD-10 Finland
Cerebral amyloid angiopathy
+∞
64.3
58
*
I69.3
ICD-10 Finland
Sequelae of cerebral infarction
262.5
57.5
56
*
AA1AD
NOMESCO Finland
CT of head and brain
9.6
51.6
137
402
I63.9
ICD-10 Finland
Cerebral infarction, unspecified
98.6
47.8
51
7
PA7AD
NOMESCO Finland
CT angiography of head and neck vasculature
15.1
40.6
39
32
I61.9
ICD-10 Finland
Intracerebral haemorrhage, unspecified
+∞
36.7
34
*
I69.1
ICD-10 Finland
Sequelae of intracerebral haemorrhage
+∞
34.4
32
*
I61.1
ICD-10 Finland
Intracerebral haemorrhage in hemisphere, cortical
+∞
33.3
31
*
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
5.5
30.4
91
270
I61.0
ICD-10 Finland
Intracerebral haemorrhage in hemisphere, subcortical
+∞
28.9
27
*
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
7.9
27.4
43
68
R41.8
ICD-10 Finland
Other and unspecified symptoms and signs involving cognitive functions and awareness
5.6
23.6
56
133
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
9.9
23.4
29
34
G45.9
ICD-10 Finland
Transient cerebral ischaemic attack, unspecified
6.4
22.7
44
86
E85.9
ICD-10 Finland
Amyloidosis, unspecified
234.7
21.0
21
*
P20
ICPC
Memory disturbance
4.2
19.9
75
254
K90
ICPC
Stroke/cerebrovascular accident
41.1
18.0
22
6
I63.3
ICD-10 Finland
Cerebral infarction due to thrombosis of cerebral arteries
197.7
17.8
18
*
I63.5
ICD-10 Finland
Cerebral infarction due to unspecified occlusion or stenosis of cerebral arteries
+∞
15.8
15
*
R4120
NOMESCO Finland
Occupational therapy
6.2
13.3
24
43
N03AX14
ATC
levetiracetam; systemic
15.6
13.1
21
15
R51.80
ICD-10 Finland
Headache
3.8
12.7
46
147
N06DX01
ATC
memantine; oral
4.0
12.4
41
123
G40.9
ICD-10 Finland
Epilepsy, unspecified
10.7
11.6
22
23
E85.4
ICD-10 Finland
Organ-limited amyloidosis
+∞
11.6
11
*
A28
ICPC
Limited function/disability NOS
3.1
11.5
66
280
PA6DE
NOMESCO Finland
Neck artery ultrasound examination with Doppler method
6.1
11.4
21
38
G40.29
ICD-10 Finland
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures
18.5
11.4
17
10
AA5BD
NOMESCO Finland
CT of cerebral ischaemia
26.9
11.3
15
6
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
12.3
10.8
19
17
FM1BE
NOMESCO Finland
Cardiac ultrasound examination through oesophagus
4.4
10.8
29
74
XA800
NOMESCO Finland
Neuropsychological investigation
15.4
10.7
17
12
N19
ICPC
Speech disorder
34.7
10.5
13
*
N03AF02
ATC
oxcarbazepine; oral
10.9
9.8
18
18
R47.0
ICD-10 Finland
Dysphasia and aphasia
58.0
9.8
11
*
R41.0
ICD-10 Finland
Disorientation, unspecified
7.6
9.6
22
32
G40.22
ICD-10 Finland
Complex partial epileptic seizure with secondary generalization
13.3
9.6
16
13
K91
ICPC
Cerebrovascular disease
23.1
9.5
13
6
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.7
9.5
131
851
I61.6
ICD-10 Finland
Intracerebral haemorrhage, multiple localized
+∞
9.4
9
*
I67.8
ICD-10 Finland
Other specified cerebrovascular diseases
+∞
9.4
9
*
I63.4
ICD-10 Finland
Cerebral infarction due to embolism of cerebral arteries
+∞
9.4
9
*
R56.8
ICD-10 Finland
Other and unspecified convulsions
5.0
9.3
21
46
PA6AD
NOMESCO Finland
CT of neck arteries
7.7
8.5
19
27
I60.9
ICD-10 Finland
Subarachnoid haemorrhage, unspecified
+∞
8.4
8
*
FFW96
NOMESCO Finland
Other operation on atria
+∞
8.4
8
*
N06DA02
ATC
donepezil; oral
3.7
8.2
28
85
R55
ICD-10 Finland
Syncope and collapse
3.2
8.1
37
135
R42
ICD-10 Finland
Dizziness and giddiness
2.6
8.1
64
314
R4130
NOMESCO Finland
Speech therapy
11.5
7.9
14
13
SPAT1216
SPAT
Assessment of functional ability
2.7
7.9
51
226
R90.8
ICD-10 Finland
Other abnormal findings on diagnostic imaging of central nervous system
19.3
7.7
11
6
L28
ICPC
Limited function/disability (L)
2.6
7.7
55
256
WX704
NOMESCO Finland
Intubation
3.8
7.5
24
69
PA2AD
NOMESCO Finland
CT angiography of brain
83.2
7.5
8
*
AAB30
NOMESCO Finland
Evacuation of spontaneous intracranial haematoma
+∞
7.3
7
*
FFM32
NOMESCO Finland
Occlusion or excision of atrial appendage transvenously with a closing device
+∞
7.3
7
*
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
16.6
7.3
11
7
I67.3
ICD-10 Finland
Progressive vascular leukoencephalopathy
16.6
7.3
11
7
PA2BD
NOMESCO Finland
Extensive CT angiography of brain
21.0
7.2
10
5
N03AG01
ATC
valproic acid; systemic, rectal
4.5
7.2
18
43
N01
ICPC
Headache
3.3
7.1
29
99
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
2.7
7.0
46
204
182
Kela drug reimbursment
Brivaracetam, eslikarbazepin, gabapentin, lacosamide, levetiracetam, perampanel, pregabalin, tiagabin and zonisamide
11.5
6.9
12
11
WX872
NOMESCO Finland
Intensive care
3.9
6.8
21
59
N03AX18
ATC
lacosamide; systemic
41.6
6.8
8
*
H53.1
ICD-10 Finland
Subjective visual disturbances
3.8
6.7
21
60
X59
ICD-10 Finland
Exposure to unspecified factor
2.5
6.4
46
213
I63.8
ICD-10 Finland
Other cerebral infarction
+∞
6.3
6
*
F01.9
ICD-10 Finland
Vascular dementia, unspecified
10.5
6.1
11
11
F06.7
ICD-10 Finland
Mild cognitive disorder
4.3
6.0
16
40
B01AC30
ATC
platelet aggregation inhibitors excl. heparin - combinations
4.3
6.0
16
40
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
25
33
8.57
18.28
1.2
1.2
2.32
24.21
e6/l
0.49
19
24
152
1012
3.51
11.58
9.3
7.5
1.22
1.21
mmol/l
0.61
132
854
142
918
3.16
11.19
7.0
6.7
1.21
1.21
mmol/l
0.00
131
824
16
10
17.32
10.55
1.1
1.1
—
—
—
0
0
75
356
2.83
10.51
2.4
2.0
—
—
—
0
0
136
877
2.94
10.41
6.8
5.0
34.90
35.09
g/l
0.16
130
818
134
884
2.75
9.34
2.6
2.3
89.57
96.23
pmol/l
0.76
83
459
103
623
2.43
8.26
2.0
1.7
19.02
20.70
nmol/l
0.61
86
497
72
371
2.51
8.21
2.0
1.7
991.68
1266.60
nmol/l
2.47
59
277
10
5
20.98
7.21
1.2
1.0
—
—
—
0
0
14
16
9.35
7.18
1.1
1.1
—
—
—
0
0
14
16
9.35
7.18
1.1
1.1
—
—
—
0
0
166
1299
3.20
7.11
5.7
4.6
14.68
13.50
mm/h
0.42
158
1179
12
11
11.55
6.90
1.2
1.1
—
—
—
0
0
54
265
2.45
6.66
2.6
1.9
—
—
—
0
0
171
1380
3.39
6.54
8.9
8.9
76.27
81.12
u/l
1.37
161
1301
118
815
2.18
6.25
2.7
2.5
80.70
80.13
nmol/l
0.08
108
699
119
833
2.15
5.98
2.9
3.0
—
—
estimate
—
0
0
182
1599
4.28
5.76
6.8
7.7
39.70
40.21
mmol/mol
0.36
171
1473
8
5
16.60
5.46
1.0
1.2
—
—
—
0
0
69
406
2.10
5.37
7.1
3.7
156.18
282.74
ng/l
0.48
62
352
182
1614
4.03
5.25
6.1
5.8
4.25
4.43
mmol/l
1.63
172
1468
10
12
8.72
5.12
1.1
1.0
—
—
—
0
0
48
251
2.22
5.00
2.7
2.0
—
—
—
0
0
181
1604
3.71
4.92
6.0
5.7
1.41
1.45
mmol/l
0.82
172
1449
178
1534
3.54
4.81
5.5
5.5
1.91
2.03
mu/l
0.75
167
1369
183
1643
4.09
4.76
6.9
6.8
2.39
2.54
mmol/l
1.54
174
1494
8
8
10.37
4.56
1.1
1.3
—
—
—
0
0
79
515
1.91
4.45
2.0
2.1
2.71
2.95
mg/l
0.32
67
444
20
73
2.94
4.34
1.4
1.9
—
—
—
0
0
45
249
2.06
4.00
5.0
5.5
32.18
33.08
%
0.23
34
154
18
66
2.91
3.88
1.5
1.7
—
—
—
0
0
108
801
1.81
3.87
5.2
4.2
46.89
40.09
ng/l
0.21
93
646
106
785
1.79
3.79
2.7
2.3
—
—
—
0
0
76
514
1.80
3.66
4.9
3.6
0.00
0.15
estimate
0.50
21
163
151
1254
1.99
3.65
3.9
4.4
15.36
15.12
pmol/l
0.48
141
1112
27
130
2.26
3.38
1.6
1.7
—
—
—
0
0
68
456
1.77
3.31
2.3
2.6
—
—
—
0
0
119
935
1.73
3.25
5.2
4.3
0.00
0.00
estimate
-0.00
26
205
121
958
1.72
3.19
5.3
4.3
0.00
1.55
estimate
0.50
24
193
25
120
2.25
3.15
1.7
3.5
2.09
2.24
mmol/l
0.10
18
95
184
1712
3.37
3.02
16.5
13.6
22.79
24.40
u/l
1.33
177
1654
119
946
1.69
3.01
5.3
4.3
0.00
7.70
estimate
0.50
26
211
5
5
10.22
2.99
1.0
1.0
—
—
—
0
0
126
1019
1.70
2.97
9.1
9.8
4.74
4.28
e9/l
0.56
111
889
173
1545
2.34
2.93
4.8
4.7
1.17
1.25
mmol/l
1.37
161
1379
15
61
2.58
2.69
1.3
1.6
—
—
—
0
0
5
7
7.30
2.56
1.0
1.0
—
—
—
0
0
178
1628
2.48
2.51
5.9
6.1
5.99
6.09
mmol/l
0.49
165
1478
25
132
2.03
2.50
4.0
8.3
25.94
24.62
mmol/l
2.17
25
132
17
80
2.24
2.26
1.6
2.7
22.86
24.97
mmol/l
0.84
17
80
93
729
1.54
2.25
2.2
2.0
1.12
1.28
mmol/l
2.39
84
585
5
9
5.67
2.22
2.4
2.1
123.40
61.41
ng/l
—
5
9
63
454
1.58
2.20
1.7
1.8
204082050.04
446.40
pmol/l
0.49
49
369
81
619
1.54
2.18
2.4
2.4
57.61
57.01
u/l
0.07
76
577
6
14
4.39
2.17
1.0
1.1
—
—
—
0
0
76
577
1.53
2.09
3.8
3.0
29.74
33.74
u/l
0.59
70
545
90
712
1.50
2.03
5.6
4.2
0.00
0.02
estimate
0.50
22
168
38
250
1.65
1.90
8.2
7.7
1.33
0.88
mmol/l
0.34
32
211
7
166
0.40
1.90
1.9
1.4
—
—
—
0
0
7
23
3.12
1.81
1.3
1.4
—
—
—
0
0
7
24
2.99
1.74
7.0
2.5
11.57
10.37
mmol/l
—
7
24
7
26
2.76
1.59
1.0
1.5
—
—
—
0
0
89
728
1.42
1.58
2.9
3.1
159.15
155.33
ug/l
0.05
78
662
26
164
1.68
1.53
4.1
4.0
86.05
85.49
ng/l
0.01
21
144
13
65
2.07
1.52
1.4
1.7
—
—
—
0
0
6
21
2.92
1.52
1.8
1.8
—
—
—
0
0
85
694
1.41
1.50
4.6
3.7
2.34
2.36
mmol/l
0.90
80
616
6
22
2.78
1.44
1.2
2.0
—
—
—
0
0
25
159
1.66
1.43
3.4
4.4
1.22
1.22
mmol/l
0.03
25
137
12
60
2.07
1.41
1.9
2.7
8.32
7.86
kpa
0.42
12
60
6
23
2.66
1.38
1.2
1.9
—
—
—
0
0
54
414
1.43
1.34
5.8
4.7
1.02
1.02
kg/l
0.04
37
281
10
48
2.14
1.30
1.5
1.7
—
—
—
0
0
11
57
1.99
1.19
1.3
1.2
—
—
—
0
0
96
826
1.33
1.13
5.6
6.6
2.12
2.65
ug/l
0.58
88
736
8
40
2.04
1.13
1.5
1.8
—
—
—
0
0
8
41
1.99
1.10
1.3
1.4
—
—
—
0
0
36
266
1.44
1.09
4.5
4.9
238.19
252.68
u/l
0.33
36
253
52
411
1.37
1.07
2.2
1.7
1.42
1.77
mg/l
0.50
43
330
86
735
1.31
1.04
2.7
3.4
1558.89
1333.34
ng/l
0.22
77
641
67
554
1.32
1.02
6.1
4.1
0.00
0.01
estimate
0.50
21
190
20
135
1.54
0.93
1.8
1.6
—
—
—
0
0
27
195
1.45
0.93
10.4
7.2
9.77
10.47
mmol/l
0.23
27
186
10
56
1.83
0.89
1.5
1.7
—
—
—
0
0
16
105
1.57
0.85
1.6
2.4
1.52
1.52
g/l
0.01
16
95
0
24
0.00
0.79
0.0
4.2
—
—
—
0
0
10
59
1.73
0.77
1.5
1.8
—
—
—
0
0
76
660
1.25
0.77
4.4
5.6
19.83
22.33
%
1.12
32
376
26
195
1.39
0.74
1.7
2.4
8.80
6.29
ug/l
0.47
21
174
7
38
1.87
0.74
3.7
2.7
9.86
9.48
pmol/l
—
7
38
57
482
1.26
0.72
3.0
3.4
354.62
369.22
umol/l
0.43
50
407
28
215
1.35
0.70
5.7
3.8
—
—
—
0
0
32
252
1.32
0.68
3.3
4.1
5.75
50.26
ug/l
0.83
26
215
5
28
1.81
0.66
1.0
1.2
—
—
—
0
0
5
28
1.81
0.66
1.0
1.2
—
—
—
0
0
66
573
1.23
0.66
4.8
3.7
0.10
0.31
e6/l
2.97
58
423
8
50
1.63
0.62
1.4
1.7
—
—
—
0
0
11
72
1.56
0.60
3.7
2.1
0.00
0.00
g/l
-0.00
11
67
0
22
0.00
0.59
0.0
1.2
—
—
—
0
0
166
1595
1.32
0.59
23.7
19.3
71.34
73.07
ml/min/173m2
0.57
160
1499
27
216
1.29
0.53
4.2
4.0
6.02
5.80
kpa
0.64
27
208
9
64
1.43
0.52
1.2
1.3
—
—
—
0
0
10
70
1.45
0.42
4.0
2.1
0.00
0.00
g/l
—
10
63
0
16
0.00
0.41
0.0
1.2
—
—
—
0
0
0
19
0.00
0.39
0.0
1.2
—
1.33
—
0
13
0
19
0.00
0.39
0.0
1.1
—
170.83
—
0
6
12
89
1.37
0.39
2.8
3.7
—
—
—
0
0
6
41
1.48
0.36
1.2
2.0
—
—
—
0
0
6
42
1.44
0.36
1.2
1.2
—
—
—
0
0
126
1316
0.87
0.35
38.6
24.0
13.88
13.85
%
0.08
126
1306
7
53
1.33
0.31
1.7
1.3
—
—
—
0
0
16
130
1.25
0.30
1.6
2.7
0.63
0.64
%
0.05
16
130
26
224
1.19
0.29
5.3
8.1
—
—
—
0
0
16
133
1.22
0.25
1.6
2.7
1.08
1.23
%
0.33
16
133
5
39
1.29
0.23
1.0
1.2
43.74
22.54
u/l
—
5
33
21
182
1.17
0.22
2.0
3.0
3.99
4.19
kpa
0.33
21
176
0
11
0.00
0.21
0.0
1.4
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
10.04
—
0
10
0
10
0.00
0.21
0.0
5.0
—
230.40
—
0
10
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
5
68
0.73
0.17
1.2
1.6
—
—
—
0
0
33
304
1.10
0.16
1.2
1.3
120.22
44.74
iu/ml
0.64
18
96
14
121
1.17
0.15
3.4
4.1
24.69
23.93
mmol/l
0.55
14
121
21
189
1.12
0.14
1.3
1.4
—
—
—
0
0
12
103
1.18
0.14
3.8
3.4
26.17
25.27
mmol/l
0.47
12
97
10
117
0.85
0.13
2.2
3.8
58.12
45.27
%
—
10
112
35
330
1.07
0.10
4.1
3.7
1.81
1.77
e6/l
0.02
19
177
12
106
1.14
0.10
1.8
1.3
—
—
—
0
0
5
45
1.11
0.10
1.4
1.5
—
—
—
0
0
5
45
1.11
0.10
2.2
1.4
—
—
—
0
0
7
68
1.03
0.08
1.1
1.0
—
—
—
0
0
20
214
0.93
0.07
3.1
3.0
5.80
10.13
umol/l
2.01
20
193
72
738
0.96
0.07
4.3
4.3
9.66
7.08
mg/mmol
0.30
49
463
47
483
0.96
0.04
3.1
3.7
0.76
0.80
ug/l
0.17
32
350
14
150
0.93
0.04
2.0
2.9
60.00
62.26
ml/min/173m2
—
7
72
27
281
0.95
0.04
1.2
1.3
54.27
18.59
u/ml
—
6
93
17
164
1.04
0.00
1.5
1.4
—
—
—
0
0
36
358
1.01
0.00
3.8
3.5
0.55
1.02
e6/l
1.09
21
203
0
8
0.00
0.00
0.0
1.6
—
—
—
0
0
0
8
0.00
0.00
0.0
1.6
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
5
55
0.91
-0.00
1.0
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
38.41
—
0
5
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
4.2
—
10.27
—
0
6
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
4.2
—
4.61
—
0
6
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
1181.89
—
0
9
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.4
—
41.41
—
0
7
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
3.78
—
0
6
Mortality – FinRegistry
↥Association
Association between endpoint I9_CEREBAMY and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| I9_CEREBAMY | 3.173 [1.99, 5.06] | < 0.001 |
| Birth year | 0.996 [0.99, 1.0] | 0.346 |
During the follow-up period (1.1.1998 — 31.12.2019), 96 out of 255 females with I9_CEREBAMY died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| I9_CEREBAMY | 3.149 [2.01, 4.93] | < 0.001 |
| Birth year | 0.989 [0.98, 1.0] | 0.018 |
During the follow-up period (1.1.1998 — 31.12.2019), 116 out of 278 males with I9_CEREBAMY died.
Mortality risk
Mortality risk for people of age
years, who have I9_CEREBAMY.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.33% | 0.564% |
| 5 | 2.108% | 3.809% |
| 10 | 4.917% | 9.085% |
| 15 | 9.426% | 16.378% |
| 20 | 15.814% | 27.056% |
Relationships between endpoints
↥Index endpoint: I9_CEREBAMY – Cerebral amyloid angiopathy
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data